Design and in vitro evaluation of effervescent gastric floating drug delivery systems of propanolol HCl;Diseño y evaluación in vitro de sistemas de administración de tabletas flotantes gástricas everfescentes de HCl propanolol

Investigacion Clinica

Volumn 53, Issue 1, 2012, Pages 60-70

  Meka, Venkata Srikanth ^a   Songa, Ambedkar Sunil ^a   Nali, Sreenivasa Rao ^a   Battu, Janaki Ram ^a   Kolapalli, Venkata Ramana Murthy ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Effervescent; Floating system; In vitro buoyancy; Polyethylene oxide; Propranolol HCl

Indexed keywords

BICARBONATE; MACROGOL; PROPRANOLOL;

ARTICLE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; EFFERVESCENT GASTRIC FLOATING DRUG DELIVERY SYSTEM; EFFERVESCENT TABLET; IN VITRO STUDY; KINETICS; PHYSICAL CHEMISTRY; STOMACH ABSORPTION; TABLET FRIABILITY; TABLET HARDNESS; TABLET PROPERTY;

ABSORPTION; ADMINISTRATION, ORAL; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; MOLECULAR STRUCTURE; PHYSICOCHEMICAL PROCESSES; POLYETHYLENE GLYCOLS; PROPRANOLOL; SODIUM BICARBONATE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STEARIC ACIDS; STOMACH; TABLETS;

EID: 84859077669     PISSN: 05355133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Davis SS. Formulation strategies for absorption window. Drug Discov Today 2005, 10:249-257.
2. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol 2006, 6:501-508.
3. Chawla G, Gupta P, Koradia V, Bansal AK. Gastroretention a means to address regional variability in intestinal drug absorption. Pharma Technol 2003, 27(7): 50-68.
4. Mayavanshi AV, Gajjar SS. Floating drug delivery systems to increase gastric retention of drugs: A Review Research J Pharm and Tech 2008, 1(4): 345-348.
5. Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993, 10:143-195.
6. Dollery SC. Therapeutic Drugs. Churchill Livingstone, Edinburgh, 1991, pp. P272-P278.
7. Tripathi KD. Antihypertensive drugs, Essentials of medical pharmacology. 5th ed, New Delhi. Jaypee Brothers 2003; 235-236.
8. Indian Pharmacopoeia, Govt. Of India, Ministry of Health and Family Welfare, the Indian Pharmacopoeia Commision, Ghaziabad, India, Vol. 1, 2007, 183.
9. Srikanth MV, Sreenivasa Rao N, Sunil SA, Sharma GS, Uhumwangho MU, Ramanamurthy KV. Formulation and evaluation of gastro retentive floating drug delivery system of ofloxacin. Drug Inv Today 2011; 3(3):7-9.
10. Lazarus J, Cooper J. Absorption, testing, and clinical evaluation of oral prolongedaction drugs. J Pharm Sci 1961, 50: 715.
11. Wagner JG. Interpretation of percent dissolved- time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci 1969, 58:1253.
12. Higuchi T. Mechanism of sustained action medication: Theoretical analysis of rate release of solid drugs dispersed in solid matrices. J Pharm Sci 1963, 52: 1145-1149.
13. Korsmeyer R, Gurny R, Peppas N. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983, 15: 25-35.
14. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation (I) theoretical consideration. Ind Eng Chem 1931, 23: 923-931.
15. Srikanth MV, Uhumwangho MU, Sreenivasa Rao N, Sunil SA, Janaki Ram B, Ramana Murthy KV. Formulation and evaluation of gastro retentive floating drug delivery system for propranolol HCl. J Pharm Allied Sci 2011, 8(2):1239-1248.
16. US Pharmacopoeia 30-NF25, The official compendia of standards, National Publishing, Philadelphia, PA, pp. 3058.
17. Shivanand P, Viral D, Shukla P, Rathanand M. Development and in vitro evaluation of propranolol hydrochloride based gastro-retentive floating tablet. Der Pharmacia Lettre 2010, 2 (1): 75-86.